Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

抗体-药物偶联物 喜树碱 抗体 细胞毒性 人源化抗体 DU145型 癌症研究 结合 化学 细胞培养 单克隆抗体 分子生物学 癌细胞 癌症 生物 医学 免疫学 体外 生物化学 内科学 数学分析 遗传学 数学 LNCaP公司
作者
Sam Lawn,Andrea Hernández Rojas,Raffaele Colombo,Dayananda Siddappa,Jodi Wong,Kaylee J. Wu,Vincent Fung,Dunja Urosev,Luying Yang,Jamie R. Rich,Stuart D. Barnscher
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 2641-2641 被引量:3
标识
DOI:10.1158/1538-7445.am2023-2641
摘要

Abstract Background: Folate Receptor alpha (FRa) is a validated cell surface cancer target that is prevalently expressed in multiple cancers with high unmet need, including ovarian cancer and other gynecological cancers, while exhibiting minimal expression in normal tissues. Due to FRa’s favorable expression profile, multiple antibody-drug conjugates (ADCs) are being explored in this setting. Here we present the preclinical characterization of a new anti-FRa ADC, ZW191. ZW191 is an antibody drug conjugate (ADC) comprised of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor payload, ZD06519, via a maleimidocaproyl (MC) anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker at a drug-to-antibody ratio (DAR) of 8. Materials and Methods: The novel antibody and drug-linker components of ZW191 were generated, characterized, and optimally integrated. The apparent binding affinity and cellular internalization of the ZW191 antibody, and the intracellular concentration of the released camptothecin payload, ZD06519, were determined in FRa-expressing cells. Additionally, the binding specificity of the ZW191 antibody was determined using a cell microarray technology to test for binding against over 6,000 full length proteins that are individually over-expressed in human cells. Tumor spheroid cancer cell cultures were utilized to determine the cytotoxicity of ZW191 and the ability of ZW191 to penetrate the layers of the three-dimensional (3D) spheroid. The bystander activity of ZW191 was assessed using antigen positive and negative co-culture experiments. The anti-tumor activity of ZW191 was evaluated in a panel of cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) ovarian cancer models spanning a range of FRa expression. ZW191 was evaluated in toxicology and pharmacokinetic (PK) studies performed in rodents and non-human primates (NHP). Results: The antibody component of ZW191 features a favorable binding profile with strong and exclusive binding to FRa, and drives superior tumor spheroid penetration, cellular internalization, and payload delivery compared to FRa targeted antibodies used in other ADCs. ZW191 demonstrates potent activity in FRa expressing 3D tumor spheroid cultures and effective bystander activity. In a panel of CDX and PDX models representing a range of FRa expression, ZW191 demonstrates compelling anti-tumor activity at exposures that are estimated to be readily achievable in the clinic. ZW191 was tolerated up to 200 mg/kg in a two-dose rat study and at 30 mg/kg in a two-dose NHP study, with favorable PK. The promising efficacy, tolerability, and PK supports the potential of ZW191 as a novel therapeutic agent that may help address unmet need in patients with high and low FRa-expressing cancers. Citation Format: Sam Lawn, Andrea Hernandez Rojas, Raffaele Colombo, Dayananda Siddappa, Jodi Wong, Kaylee Wu, Vincent Fung, Dunja Urosev, Luying Yang, Jamie R. Rich, Stuart D. Barnscher. ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2641.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
下雨天发布了新的文献求助10
刚刚
自由发布了新的文献求助10
1秒前
1秒前
1秒前
Shoujiang发布了新的文献求助10
2秒前
张硕完成签到 ,获得积分20
2秒前
铁锅炖大鹅完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
舒适平文发布了新的文献求助10
3秒前
3秒前
凝歆发布了新的文献求助20
3秒前
4秒前
布林发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
5秒前
qc发布了新的文献求助10
5秒前
Milder完成签到,获得积分10
5秒前
11发布了新的文献求助10
5秒前
5秒前
carinaaaa完成签到,获得积分10
5秒前
流星雨完成签到 ,获得积分10
5秒前
5秒前
打打的应助被zy采纳,获得10
6秒前
郝Hao发布了新的文献求助10
6秒前
曙光发布了新的文献求助10
6秒前
6秒前
超哥哥发布了新的文献求助10
7秒前
NexusExplorer的应助被小爱同学采纳,获得10
7秒前
7秒前
等待的博完成签到,获得积分20
7秒前
aaa发布了新的文献求助10
8秒前
威alisa发布了新的文献求助10
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8162816
求助须知:如何正确求助?哪些是违规求助? 9557103
关于积分的说明 21738393
捐赠科研通 7753330
什么是DOI,文献DOI怎么找? 3427963
关于科研通互助平台的介绍 2552742
邀请新用户注册赠送积分活动 2472556